Aiolos Bio secures $245M Series A to develop breakthrough asthma treatment
Aiolos Bio, founded by former Genentech executives, has raised $245 million in a Series A funding round to advance an asthma drug licensed from China. The startup plans to initiate a Phase II asthma study next year for its anti-TSLP antibody, which is its sole drug candidate. Aiolos Bio's CEO, Khurem Farooq, previously led Gyroscope Therapeutics, which was acquired by Novartis in December 2021.